Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12817362 | 0.95 | ALOX5 (0.42) | ALOX5PTGS2PPARAHTR1ADRD2 | |
| SCHEMBL7838938 | 0.87 | CA1 (0.39) | ALOX5PTGS2PPARAHTR1ADRD2 | |
| SCHEMBL64882 | 0.80 | CA1 (0.42) | ALOX5PTGS2DRD2DRD3 | |
| SCHEMBL8480841 | 0.79 | ENPP2 (0.38) | ALOX5PTGS2 | |
| SCHEMBL7664369 | 0.77 | NPC1 (0.37) | PTGS2 | |
| SCHEMBL815744 | 0.77 | KCNH2 (0.40) | PTGS2KCNH2 | |
| SCHEMBL406610 | 0.77 | LIPG (0.46) | ALOX5PTGS2PPARAPPARGKCNH2 | |
| SCHEMBL5206377 | 0.76 | GABRA1 (0.39) | ALOX5PTGS2HTR1ADRD2DRD3 | |
| SCHEMBL8093384 | 0.76 | ABCB1 (0.47) | ALOX5KCNH2 | |
| SCHEMBL21523319 | 0.75 | LIPG (0.49) | ALOX5PTGS2PPARAPPARGKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1438284-B1 | SYNTHESIS OF ( )-2-((DIMETHYLAMINO)METHYL)-1-(ARYL)CYCLOHEXANOLS | EURO CELTIQUE SA (LU) | 2007-09-26 | — | — | EP | claimed |
| US-20040024209-A1 | 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | SCHNUTE MARK E (US) | 2004-02-05 | — | — | US | disclosed |
| US-6653307-B2 | Such as N-(4-chlorobenzyl)-6-(4-morpholinylmethyl)-4-oxo-1-phenyl-1,4-dihydro-3-quinolinecarboxamide for treatment of herpes virus; viral DNA polymerase inhibitors | PHARMACIA & UPJOHN COMPANY | 2003-11-25 | — | — | US | disclosed |
| EP-1292575-A2 | 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-03-19 | — | — | EP | disclosed |
| US-20020103220-A1 | 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-08-01 | — | — | US | disclosed |
| WO-2001098275-A2 | 1-ARYL-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024209-A1 | 1-Aryl-4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents | ZC3HAV1, ZC3HAV1L, IRF3 | ALOX5 4135/4885PTGS2 2797/4885PPARA 4131/4885 |
| US-20020103220-A1 | 1-Aryl-4oxo-1,4-Dihydro-3-quinolinecarboxamides as antiviral agents | ZC3HAV1, IRF3, ZC3HAV1L | ALOX5 3614/4885PTGS2 2256/4885PPARA 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.